Journal of Parkinsons Disease

Papers
(The median citation count of Journal of Parkinsons Disease is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
This is NOT the End for Immunotherapy in Parkinson’s Disease – A Perspective from Early Drug Development Scientists121
Clinical Trial Highlights: Modulators of Mitochondrial Function96
Introduction: The Earliest Phase of Parkinson’s Disease: Possibilities for Detection and Intervention77
One-year practice effects predict long-term cognitive outcomes in Parkinson's disease64
Chronotropic Incompetence in Parkinson’s Disease: A Possible Marker of Severe Disease Phenotype?62
A framework to standardize gait study protocols in Parkinson's disease61
A Multisensory Deficit in the Perception of Pleasantness in Parkinson’s Disease52
Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson’s Disease Progression52
May Bradykinesia Features Aid in Distinguishing Parkinson’s Disease, Essential Tremor, And Healthy Elderly Individuals?50
Ethical Considerations for Identifying Individuals in the Prodromal/Early Phase of Parkinson’s Disease: A Narrative Review50
Cost-Effectiveness and Cost-Utility of Early Levodopa in Parkinson’s Disease50
Apathy Reflects Extra-Striatal Dopaminergic Degeneration in de novo Parkinson’s Disease48
The Role of Microelectrode Recording and Stereotactic Computed Tomography in Verifying Lead Placement During Awake MRI-Guided Subthalamic Nucleus Deep Brain Stimulation for Parkinson’s Disease45
Real-World Evaluation of the Feasibility, Acceptability and Safety of a Remote, Self-Management Parkinson’s Disease Care Pathway: A Healthcare Improvement Initiative44
Predictive Value of Verbatim Parkinson’s Disease Patient-Reported Symptoms of Postural Instability and Falling43
Jellinger K, “Parkinson’s Disease and Dementia with Lewy Bodies: One and the Same”42
What medicines do people with Parkinson's disease want?42
Post-Traumatic Stress Disorder and Risk of Parkinson’s Disease in a Veteran Cohort41
Reply to the Letter to the Editor: Stefani A, “Is it too early to Underrate Genetic onto PD Pathogenesis? Reflections on History”40
Effects of Very Low- and High-Frequency Subthalamic Stimulation on Motor Cortical Oscillations During Rhythmic Lower-Limb Movements in Parkinson’s Disease Patients40
Evading the Immune System: Immune Modulation and Immune Matching in Cell Replacement Therapies for Parkinson’s Disease39
Rapid Voluntary Blinking as a Clinical Marker of Parkinson’s Disease39
No Higher Risk-Seeking Tendencies or Altered Self-Estimation in a Social Decision-Making Task in Patients with Parkinson’s Disease38
The fixel GI Parkinson's research and integrated support model (PRISM)38
Clinical Trial Highlights – Aerobic Exercise for Parkinson’s Disease37
Is There an Association Between Parkinson’s Disease and Periodontitis? A Systematic Review and Meta-Analysis36
A Coalition to Advance Treatments for Parkinson’s Disease, Dementia with Lewy Bodies, and Related Disorders35
Cerebral Small Vessel Disease Is Associated with Motor, Cognitive, and Emotional Dysfunction in Multiple System Atrophy33
Are Preformed Fibrils a Model of Parkinson’s Disease?32
Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson’s Disease31
Imaging Biomarkers in Prodromal and Earliest Phases of Parkinson’s Disease31
Metabotropic Glutamate Receptor 4 (mGlu4) Positive Allosteric Modulators Lack Efficacy in Rat and Marmoset Models of L-DOPA-Induced Dyskinesia30
Atrophy-related corticospinal changes in advanced Parkinson's disease are associated with the genetic etiology of the disease30
Association of Dynamic Changes in Metabolic Syndrome Status with the Risk of Parkinson’s Disease: A Nationwide Cohort Study30
A possible pathway to freezing of gait in Parkinson's disease30
Early-Onset Parkinson’s Disease: Creating the Right Environment for a Genetic Disorder30
Surveying Global Availability of Parkinson’s Disease Treatment29
Nomogram to Predict the Probability of Functional Dependence in Early Parkinson’s Disease29
Burden of tremor in Parkinson's disease: A survey study29
Nigral Iron Deposition Influences Disease Severity by Modulating the Effect of Parkinson’s Disease on Brain Networks29
Modulation of Cerebellar Oscillations with Subthalamic Stimulation in Patients with Parkinson’s Disease28
Burden, Anxiety, and Depression Among Caregivers of Parkinson’s Disease Patients27
Deficient Interhemispheric Connectivity Underlies Movement Irregularities in Parkinson’s Disease27
Metabolic connectivity of freezing in Parkinson's disease27
Mild cognitive impairment is not predictive of dementia up to 15 years after subthalamic deep brain stimulation in Parkinson's disease26
Mortality and causes of death in patients with Parkinson's disease in Taiwan26
Localized Pantothenic Acid (Vitamin B5) Reductions Present Throughout the Dementia with Lewy Bodies Brain26
Taste Impairments in a Parkinson’s Disease Model Featuring Intranasal Rotenone Administration in Mice26
Gene Therapy to Modulate Alpha-Synuclein in Synucleinopathies25
DNA Methylation Signature of Aging: Potential Impact on the Pathogenesis of Parkinson’s Disease24
Nomogram for Early Prediction of Parkinson’s Disease Based on microRNA Profiles and Clinical Variables24
Feasibility and Proof-of-Concept of Delivering an Autonomous Music-Based Digital Walking Intervention to Persons with Parkinson’s Disease in a Naturalistic Setting24
Twenty-five-year experience with apomorphine pump in Parkinson's disease: A real-life long-term retrospective tolerance study24
Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson’s Disease23
The Compound ATH434 Prevents Alpha-Synuclein Toxicity in a Murine Model of Multiple System Atrophy23
Acknowledgment to Reviewers 202222
Neuropsychiatric Burden Is a Predictor of Early Freezing and Motor Progression in Drug-Naïve Parkinson’s Disease22
Neuroinflammation and Immune Changes in Prodromal Parkinson’s Disease and Other Synucleinopathies22
The Role of Diet in Parkinson’s Disease22
Hidden Gems in Neurology: The Syndrome of Hemiparkinsonism-Hemiatrophy22
Bringing Advanced Therapies for Parkinson’s Disease to the Clinic: The Scientist’s Perspective21
A dose-finding study shows terazosin enhanced energy metabolism in neurologically healthy adults20
Symmetric and Profound Monoaminergic Degeneration in Parkinson’s Disease with Premotor REM Sleep Behavior Disorder20
Gait Declines Differentially in, and Improves Prediction of, People with Parkinson’s Disease Converting to a Freezing of Gait Phenotype20
Locus Coeruleus Degeneration Correlated with Levodopa Resistance in Parkinson’s Disease: A Retrospective Analysis20
A Summary of Phenotypes Observed in the In Vivo Rodent Alpha-Synuclein Preformed Fibril Model19
Multiple Pathways of LRRK2-G2019S/Rab10 Interaction in Dopaminergic Neurons19
Recruitment for Remote Decentralized Studies in Parkinson’s Disease19
Do Impulse Control Disorders Impair Car Driving Performance in Patients with Parkinson’s Disease?19
Specific Detection of Physiological S129 Phosphorylated α-Synuclein in Tissue Using Proximity Ligation Assay19
Motor Memory Consolidation Deficits in Parkinson’s Disease: A Systematic Review with Meta-Analysis19
Effects of 6 months of endurance exercise on motor function, exercise capacity, and autonomic function based on presence of autonomic dysfunction in individuals with early Parkinson's disease18
Enhancing Trial Delivery in Parkinson’s Disease: Qualitative Insights from PD STAT18
Effects of Low-Intensity Vestibular Noise Stimulation on Postural Instability in Patients with Parkinson’s Disease18
Prevalence of Prodromal Symptoms of Parkinson’s Disease in the Late Middle-Aged Population18
Non-Pharmacological Interventions for People with Parkinson’s Disease: Are We Entering a New Era?17
Self-Reported Visual Complaints in People with Parkinson’s Disease: A Systematic Review17
Structural-Functional Correlates of Response to Pedunculopontine Stimulation in a Randomized Clinical Trial for Axial Symptoms of Parkinson’s Disease17
Enhancing the diagnostic potential of electroretinography in Parkinson's disease: A review of protocol and cohort criteria17
Enhancing Participant Engagement in Clinical Studies: Strategies Applied in the Personalized Parkinson Project17
Parkinson’s Pals: A Student-Led Program to Facilitate Intergenerational Connections and Promote Psychosocial Well-Being Among Persons with Parkinson’s Disease17
Unveiling the neural network of freezing of gait in Parkinson's disease: A coordinate-based network study17
“Tip-of-the-Tongue” Phenomenon in Parkinson’s Disease: A Hidden Gem17
Evaluating the Psychometric Properties of the Psychological Capital Questionnaire (PCQ) in Patients with Parkinson’s Disease17
Freezing of gait detection: The effect of sensor type, position, activities, datasets, and machine learning model17
Subcortical Iron Accumulation Pattern May Predict Neuropsychological Outcomes After Subthalamic Nucleus Deep Brain Stimulation: A Pilot Study17
Sex-specific progression of Parkinson's disease: A longitudinal mixed-models analysis16
Anxiety-related attentional characteristics and their relation to freezing of gait in people with Parkinson's: Cross-validation of the Adapted Gait Specific Attentional Profile (G-SAP)16
The Utility of Breath Analysis in the Diagnosis and Staging of Parkinson’s Disease16
Staging Parkinson’s Disease According to the MNCD (Motor/Non-motor/Cognition/Dependency) Classification Correlates with Disease Severity and Quality of Life16
Tackling Parkinson’s Disease as a Global Challenge16
Utility of a newly created questionnaire on subtle motor symptoms in high-risk subjects with Parkinson's disease16
Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022?16
Specialized Allied Health Care for Parkinson’s Disease: State of the Art and Future Directions16
Parkinson’s Disease and the Gut: Symptoms, Nutrition, and Microbiota16
Incretin Mimetics Restore the ER-Mitochondrial Axis and Switch Cell Fate Towards Survival in LUHMES Dopaminergic-Like Neurons: Implications for Novel Therapeutic Strategies in Parkinson’s Disease16
Integrating virtual reality into multidisciplinary care for Parkinson's disease: A narrative review16
A Practical Guide to the Evaluation of Compensation Strategies for Gait Impairment in Parkinson’s Disease15
Unmet needs in the pharmacological management of motor symptoms in Parkinson's disease15
40-Year Incidence of Early-Onset Parkinson’s Disease in Southeast Minnesota15
Feasibility and acceptability of PDConnect, a multi-component intervention to support physical activity in people with Parkinson's disease: A mixed methods study15
Tetrabenazine Mitigates Aberrant Release and Clearance of Dopamine in the Nigrostriatal System, and Alleviates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson’s Disease15
Reduced Thickness of the Retina in de novo Parkinson’s Disease Shows A Distinct Pattern, Different from Glaucoma15
Designing the First Trials for Parkinson’s Prevention15
Neurodegeneration of the Globus Pallidus Internus as a Neural Correlate to Dopa-Response in Freezing of Gait15
Remote Delivery of Allied Health Therapies in Parkinson’s Disease14
Quantitative Susceptibility Mapping and Free Water Imaging of Substantia Nigra in Parkinson’s Disease14
Trichloroethylene: An Invisible Cause of Parkinson’s Disease?14
Kinematic Effects of Combined Subthalamic and Dorsolateral Nigral Deep Brain Stimulation in Parkinson’s Disease14
Anxiety in Parkinson’s Disease Is Associated with Changes in Brain Structural Connectivity14
Gender Distribution in Deep Brain Stimulation for Parkinson’s Disease: The Effect of Awake versus Asleep Surgery14
Distinct Patterns of Gene Expression Changes in the Colon and Striatum of Young Mice Overexpressing Alpha-Synuclein Support Parkinson’s Disease as a Multi-System Process14
Discontinuation or acute unplanned cessation of oral dopaminergic medications in persons with Parkinson's disease: A practice review14
Alterations in Self-Aggregating Neuropeptides in Cerebrospinal Fluid of Patients with Parkinsonian Disorders14
Emerging Role of Environmental Epitranscriptomics and RNA Modifications in Parkinson’s Disease14
Non-Pharmacological Treatment of Autonomic Dysfunction in Parkinson’s Disease and Other Synucleinopathies14
Inflammasome Activation in Parkinson’s Disease13
Pediatric-onset PRKN disease: New insights into an understudied population13
Diffuse putaminal degeneration without iron deposition in multiple system atrophy13
Prevalence of Concomitant Pathologies in Parkinson’s Disease: Implications for Prognosis, Diagnosis, and Insights into Common Pathogenic Mechanisms13
Fatigue in de novo Parkinson’s Disease: Expanding the Neuropsychiatric Triad?13
Neuroimaging Correlates of Substantia Nigra Hyperechogenicity in Parkinson’s Disease13
Spinal Cord Stimulation for Gait Disorders in Parkinson’s Disease13
Association Between Body Mass Index Changes and All-Cause Mortality in Parkinson’s Disease13
Return on Investment Analysis for the Integrated Parkinson’s Care Network: Lesson Learned from a Pilot Study13
Intestinal biomarkers, microbiota composition, and genetic predisposition to inflammatory bowel disease as predictors of Parkinson's disease manifestation13
Advice to People with Parkinson’s in My Clinic: Orthostatic Hypotension13
Bringing Advanced Therapy Medicinal Products (ATMPs) for Parkinson’s Disease to the Clinic: The Investigator’s Perspective13
Exploring the link between personality dimensions and non-motor fluctuations in Parkinson's disease13
Non-Motor Symptom Management: Insights into Adherence to Treatment Guidelines in Parkinson’s Disease Patients13
Mycobacterium bovis Infection of a Deep Brain Stimulation System Following Intravesical Bacillus Calmette-Guérin (BCG) Instillation13
RAGE Against the Glycation Machine in Synucleinopathies: Time to Explore New Questions13
Self-Perception of Voice and Swallowing Handicap in Parkinson’s Disease13
Can People with Parkinson’s Disease Self-Trigger Gait Initiation? A Comparison of Cueing Strategies13
Natural Health Products for Symptomatic Relief of Parkinson’s Disease: Prevalence, Interest, and Awareness13
Axial Impairment Following Deep Brain Stimulation in Parkinson’s Disease: A Surgicogenomic Approach13
New insights from a Malaysian real-world deep brain stimulation cohort12
Immunological Features of LRRK2 Function and Its Role in the Gut-Brain Axis Governing Parkinson’s Disease12
Assessing the Role of Locus Coeruleus Degeneration in Essential Tremor and Parkinson’s Disease with Sleep Disorders12
Pain Fluctuations in Parkinson’s Disease and Their Association with Motor and Non-Motor Fluctuations12
Impaired Inhibitory Control During Walking in Parkinson’s Disease Patients: An EEG Study12
Non-Pharmacological Interventions for Depression and Anxiety in Parkinson’s Disease12
The Role of Pathogens and Anti-Infective Agents in Parkinson’s Disease, from Etiology to Therapeutic Implications12
Mapping Cholinergic Synaptic Loss in Parkinson’s Disease: An [18F]FEOBV PET Case-Control Study12
The Use of Image Guided Programming to Improve Deep Brain Stimulation Workflows with Directional Leads in Parkinson’s Disease12
Biofluid Detection of Pathological α-Synuclein in the Prodromal Phase of Synucleinopathies12
Depressive symptoms can negatively influence patient reported disease severity after subthalamic nucleus stimulation for Parkinson's disease12
Longitudinal Cohort Study of Verbatim-Reported Postural Instability Symptoms as Outcomes for Online Parkinson’s Disease Trials12
Risk of Neurodegeneration in Patients with Rapid Eye Movement Sleep Behavior Disorder12
The potential of distributed diagnostics for the early detection of Parkinson's disease12
Proposed mechanisms of neuroprotection for nicotine in Parkinson's disease12
Appropriateness of Applying Cerebrospinal Fluid Biomarker Cutoffs from Alzheimer’s Disease to Parkinson’s Disease12
Constipation Predicts Cognitive Decline in Parkinson’s Disease: Results from the COPPADIS Cohort at 2-Year Follow-up and Comparison with a Control Group12
Therapeutic Strategies for Immune Transformation in Parkinson’s Disease12
Retrograde Procedural Memory in Parkinson’s Disease: A Cross-Sectional, Case-Control Study11
Infections and Changes in Commensal Bacteria and the Pathogenesis of Parkinson’s Disease11
Glucocerebrosidase Mutations and Motor Reserve in Parkinson’s Disease11
Hypomimia May Influence the Facial Emotion Recognition Ability in Patients with Parkinson’s Disease11
PTEN-Induced Putative Kinase 1 Dysfunction Accelerates Synucleinopathy11
Integration of Virtual Reality into Transcranial Magnetic Stimulation Improves Cognitive Function in Patients with Parkinson’s Disease with Cognitive Impairment: A Proof-of-Concept Study11
Acknowledgment to Reviewers 202311
Machine Learning-Based Classification of Parkinson’s Disease Patients Using Speech Biomarkers11
Worsening of Parkinson’s Disease After Termination of COVID-19 Quarantine Cannot Be Reversed Despite Resumption of Physiotherapy11
Dopaminergic Cell Replacement for Parkinson’s Disease: Addressing the Intracranial Delivery Hurdle11
Why the Gut Microbiome Must Be Considered When Evaluating the Impact of Pesticides on Parkinson’s Disease Risk11
How Information Affects Patients with Parkinson’s Disease: A Scoping Review of the Literature11
Letter to the Editor: Is It Too Early to Underrate Genetics onto PD Pathogenesis? Reflections on History11
Personality Changes After Subthalamic Nucleus Stimulation in Parkinson’s Disease11
Preparing for Parkinson’s disease prevention trials: Current progress and future directions11
Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease: A Pooled Analysis of 8 Phase 2b/3 Trials11
Modeling of Parkinson’s Disease Progression and Implications for Detection of Disease Modification in Treatment Trials10
Comparative Analysis of Total Alpha-Synuclein (αSYN) Immunoassays Reveals That They Do Not Capture the Diversity of Modified αSYN Proteoforms10
Parkinson's disease participant-led research on the impact of deep brain stimulation frequency10
Increasing trends in utilization of physical and occupational therapy services in early Parkinson's disease10
Motor outcomes in unilateral, bilateral rapid, and bilateral delayed staging deep brain stimulation for Parkinson’s disease10
Using Extracellular miRNA Signatures to Identify Patients with LRRK2-Related Parkinson’s Disease10
Reaching and Grasping Movements in Parkinson’s Disease: A Review10
Concordance between imaging and clinical based STN-DBS programming improves motor outcomes of directional stimulation in Parkinson's disease10
Development of a Screening Tool for Assessing Sexual Difficulties Among Patients with Parkinson’s Disease: The PD-SDS10
Colonoscopy and Subsequent Risk of Parkinson’s Disease10
Dengue Virus Infection and Risk of Parkinson’s Disease: A Nationwide Longitudinal Study10
Screening Tools for Sarcopenia in Mild to Moderate Parkinson’s Disease: Assessing the Accuracy of SARC-F and Calf Circumference10
Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion10
Structural Connectivity of Subthalamic Nucleus Stimulation for Improving Freezing of Gait10
Disease Progression of Data-Driven Subtypes of Parkinson’s Disease: 5-Year Longitudinal Study from the Early Parkinson’s Disease Longitudinal Singapore (PALS) Cohort10
Oscillation-Specific Nodal Differences in Parkinson’s Disease Patients with Anxiety10
Insights on Genetic and Environmental Factors in Parkinson’s Disease from a Regional Swedish Case-Control Cohort10
Addressing the “Replication Crisis” in the Field of Parkinson’s Disease9
The Impact of Motor, Non-Motor, and Social Aspects on the Sexual Health of Men Living with Parkinson’s Disease9
Cardiovascular Risk Factors and Phenoconversion to Neurodegenerative Synucleinopathies in Idiopathic REM Sleep Behavior Disorder9
Premorbid Educational Attainment and Long-Term Motor Prognosis in Parkinson’s Disease9
Declining trends in the incidence of Parkinson's disease: A cohort study in Germany9
Neurofilament Light Protein Predicts Disease Progression in Idiopathic REM Sleep Behavior Disorder9
Factors Associated with Preferred Place of Care and Death in Patients with Parkinson’s Disease: A Cross-Sectional Study9
Neural Oscillations and Functional Significances for Prioritizing Dual-Task Walking in Parkinson’s Disease9
Effectiveness of Long-Term Physiotherapy in Parkinson’s Disease: A Systematic Review and Meta-Analysis9
Association Between Menopausal Hormone Therapy and Risk for Parkinson’s Disease9
Fear of Progression is Determined by Anxiety and Self-Efficacy but not Disease-Specific Parameters in Patients with Parkinson’s Disease: Preliminary Data from a Multicenter Cross-Sectional Study9
Diverse preferences, different solutions: Exploring remote monitoring preferences in Parkinson's disease through a discrete choice experiment9
Lactobacillaceae and Parkinson's disease: An apparent paradox9
Immunogenetic Determinants of Parkinson’s Disease Etiology9
Novel Outreach Program and Practical Strategies for Patients with Parkinsonism in the COVID-19 Pandemic9
Sleep Disorders in Early-Onset Parkinsonism: A Population-Based Study9
Trait Anxiety as a Risk Factor for Impulse Control Disorders in de novo Parkinson’s Disease9
DNAJB6b is Downregulated in Synucleinopathies9
Chronotropic Incompetence During Exercise Testing as a Marker of Autonomic Dysfunction in Individuals with Early Parkinson’s Disease9
An Update on Gene Therapy Approaches for Parkinson’s Disease: Restoration of Dopaminergic Function8
Impact of Visual Impairment on Vision-Related Quality of Life in Parkinson’s Disease8
The proSAAS Chaperone Provides Neuroprotection and Attenuates Transsynaptic α-Synuclein Spread in Rodent Models of Parkinson’s Disease8
Reading Difficulties in Parkinson’s Disease: A Stepped Care Model for Neurovisual Rehabilitation8
The Role of Monoaminergic Tones and Brain Metabolism in Cognition in De Novo Parkinson’s Disease8
An Evaluation of KELVIN, an Artificial Intelligence Platform, as an Objective Assessment of the MDS UPDRS Part III8
CLOVER-DBS: Algorithm-Guided Deep Brain Stimulation-Programming Based on External Sensor Feedback Evaluated in a Prospective, Randomized, Crossover, Double-Blind, Two-Center Study8
Cognitive Effects of Three β-Adrenoceptor Acting Drugs in Healthy Volunteers and Patients with Parkinson’s Disease8
Hidden Gems in the Neurological Literature of Progressive Supranuclear Palsy8
Neuropsychiatric Symptoms and Caregiver Stress in Parkinson’s Disease with Cognitive Impairment, Alzheimer’s Disease, and Frontotemporal Dementia8
Advice to people with Parkinson's in my clinic: Get a cardiopulmonary exercise test8
Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson’s Disease8
The Effect of a Structured Medication Review on Quality of Life in Parkinson’s Disease8
Neurotrophic factors for Parkinson's disease: Current status, progress, and remaining questions. Conclusions from a 2023 workshop8
mHealth-assisted expiratory muscle strength training in Parkinson's disease patients: A proof-of-concept study8
Visualization of the Movement Disorder Society Unified Parkinson’s Disease Rating Scale Results8
Freezing of Gait Before Levodopa8
A Randomized, Double-Blinded Crossover Trial of Short Versus Conventional Pulse Width Subthalamic Deep Brain Stimulation in Parkinson’s Disease8
The Etiology of Parkinson’s Disease: New Perspectives from Gene-Environment Interactions8
Opportunities and Pitfalls of REM Sleep Behavior Disorder and Olfactory Dysfunction as Early Markers in Parkinson’s Disease8
Cognition and Other Non-Motor Symptoms in an At-Risk Cohort for Parkinson’s Disease Defined by REM-Sleep Behavior Disorder and Hyposmia7
Drugs to the Rescue: Comparison of On-Demand Therapies for OFF Symptoms in Parkinson’s Disease7
Alcohol and Parkinson’s Disease: A Systematic Review and Meta-Analysis7
Pain and the Non-Pharmacological Management of Pain in People with Parkinson’s Disease7
Gaps in the Parkinson's disease therapeutic clinical pipeline: A focus on approaches targeting disease pathobiology7
The Effects of Subthalamic Nucleus Deep Brain Stimulation in Parkinson’s Disease on Associative Learning of Verbal and Non-Verbal Information by Trial and Error or with Corrective Feedback7
“No One Can Tell Me How Parkinson’s Disease Will Unfold”: A Mixed Methods Case Study on Palliative Care for People with Parkinson’s Disease and Their Family Caregivers7
Visual hallucinations in Parkinson's disease are associated with deficits in social perception7
Focused Ultrasound Thalamotomy in Tremor Dominant Parkinson’s Disease: Long-Term Results7
The Importance of Digital Health Literacy in an Evolving Parkinson’s Disease Care System7
Body-First Subtype of Parkinson’s Disease with Probable REM-Sleep Behavior Disorder Is Associated with Non-Motor Dominant Phenotype7
Considerations on How to Prevent Parkinson’s Disease Through Exercise7
Video-Based Automated Assessment of Movement Parameters Consistent with MDS-UPDRS III in Parkinson’s Disease7
Ankylosing Spondylitis: A Risk Factor for Parkinsonism—A Nationwide Population-Based Study7
Gene Therapy for Parkinson’s Disease Associated with GBA1 Mutations7
A perspective of persons with Parkinson's disease on the contribution of alpha-synuclein seed amplification assay biomarker to the diagnosis of Parkinson's disease7
Risk Factors for Postoperative Delirium Severity After Deep Brain Stimulation Surgery in Parkinson’s Disease7
Rare Variants Analysis of Lysosomal Related Genes in Early-Onset and Familial Parkinson’s Disease in a Chinese Cohort7
Digital Intervention Promoting Physical Activity in People Newly Diagnosed with Parkinson’s Disease: Feasibility and Acceptability of the Knowledge, Exercise-Efficacy and Participation (KEEP) Interven7
Which Gait Tasks Produce Reliable Outcome Measures of Freezing of Gait in Parkinson’s Disease?7
Evaluation of the Impact of Integrated Care and Self-Management After Deep Brain Stimulation in Parkinson’s Disease7
Evaluation of Bedside Tests of Attention and Arousal Assessing Delirium in Parkinson’s Disease, Dementia, and Older Adults7
Recognition, management, and patient perspectives of impulsive-compulsive disorders in Parkinson’s disease7
Dopamine-responsive post-anoxic parkinsonism7
0.16215920448303